Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding comp...
Main Authors: | Jan Beyer-Westendorf, Sandra Marten, Luise Tittl, Christiane Naue, Martin Bornhäuser |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2021-04-01
|
Series: | TH Open |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675 |
Similar Items
-
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
by: Alexander Cohen, et al.
Published: (2021-01-01) -
Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01) -
Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice
by: Stephan V. Hendriks, et al.
Published: (2020-04-01) -
Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY
by: Jan Beyer-Westendorf, et al.
Published: (2021-12-01) -
Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)